Denali Therapeutics Inc (DNLI) concluded trading on Wednesday at a closing price of $13.74, with 3.63 million shares of worth about $49.86 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.83% during that period and on April 03, 2025 the price saw a gain of about 11.80%. Currently the company’s common shares owned by public are about 142.63M shares, out of which, 125.71M shares are available for trading.
Stock saw a price change of -0.51% in past 5 days and over the past one month there was a price change of -13.86%. Year-to-date (YTD), DNLI shares are showing a performance of -32.58% which decreased to -33.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.05 but also hit the highest price of $33.33 during that period. The average intraday trading volume for Denali Therapeutics Inc shares is 1.15 million. The stock is currently trading -6.54% below its 20-day simple moving average (SMA20), while that difference is down -25.79% for SMA50 and it goes to -40.52% lower than SMA200.
Denali Therapeutics Inc (NASDAQ: DNLI) currently have 142.63M outstanding shares and institutions hold larger chunk of about 88.02% of that.
The stock has a current market capitalization of $2.00B and its 3Y-monthly beta is at 1.53. It has posted earnings per share of -$2.58 in the same period. It has Quick Ratio of 8.46 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DNLI, volatility over the week remained 11.11% while standing at 7.02% over the month.
Stock’s fiscal year EPS is expected to drop by -12.76% while it is estimated to increase by 10.84% in next year. EPS is likely to grow at an annualized rate of 7.03% for next 5-years, compared to annual growth of -4.46% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on March 07, 2025 offering an Overweight rating for the stock and assigned a target price range of between $41 and $33 to it. Coverage by Deutsche Bank stated Denali Therapeutics Inc (DNLI) stock as a Buy in their note to investors on February 11, 2025, suggesting a price target of $31 for the stock. Stock get a Buy rating from Stifel on December 16, 2024.
